FDA Approved: LUNESTA — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

The FDA approved a supplemental application for Lunesta (eszopiclone) from Waylis Therapeutics LLC. The action involves changes to Lunesta's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Lunesta (eszopiclone)

Snippet

SUPPL AP for LUNESTA (ESZOPICLONE)